Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Sees Large Decrease in Short Interest

Hansa Biopharma AB (publ) (OTCMKTS:HNSBFGet Rating) was the target of a large decrease in short interest in the month of July. As of July 15th, there was short interest totalling 334,100 shares, a decrease of 18.6% from the June 30th total of 410,600 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upped their target price on Hansa Biopharma AB (publ) from SEK 223 to SEK 244 and gave the stock a “buy” rating in a research note on Wednesday, July 20th.

Hansa Biopharma AB (publ) Price Performance

OTCMKTS HNSBF opened at $5.66 on Thursday. The business has a fifty day moving average price of $5.66 and a 200 day moving average price of $7.28. Hansa Biopharma AB has a one year low of $5.66 and a one year high of $10.29.

About Hansa Biopharma AB (publ)

(Get Rating)

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome.

Read More

Receive News & Ratings for Hansa Biopharma AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hansa Biopharma AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.